Biodesix Confirms Prognostic Value of VeriStrat Testing in Phase 3 Study of Patients with Advanced Lung Cancer
August 29, 2018 08:21 ET
|
Biodesix, Inc.
BOULDER, Colo., Aug. 29, 2018 (GLOBE NEWSWIRE) -- A new study published in The Oncologist demonstrates the objective prognostic value of the Biodesix VeriStrat® test in patients with non-small cell...
New Data Demonstrate the Biodesix VeriStrat® Liquid Biopsy Test Reliably Informs Lung Cancer Treatment Decisions
April 30, 2018 09:20 ET
|
Biodesix, Inc.
- First Data Showing Prognostic Value of Test Among Patients by Performance Status Presented at ACMQ Annual Meeting – - Optimizing Best Supportive Care and Avoiding Overtreatment Creates an Expected...
Interim Results from Biodesix® Study Indicate That VeriStrat Testing Impacts Treatment Decisions Across All Stages of Non-Small Cell Lung Cancer
September 15, 2017 11:55 ET
|
Biodesix, Inc.
BOULDER, Colo., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Interim analysis of a new study examining the impact of VeriStrat testing on treatment decisions in patients with non-small cell lung cancer...
Lung Cancer: VeriStrat® Test Identifies Patients with Squamous Cell Carcinoma of the Lung Who Are More Likely to Have Improved Survival on Afatinib Therapy
July 10, 2017 13:09 ET
|
Biodesix, Inc.
BOULDER, Colo., July 10, 2017 (GLOBE NEWSWIRE) -- Clinical findings published in the peer reviewed journal Lung Cancer show that the Biodesix® VeriStrat test is prognostic for outcomes in patients...